Ray Kaczmarek named Chief Technology and Manufacturing Officer of Nanoscope Therapeutics
Kaczmarek has a notable background of executive leadership and operational expertise in the gene therapy manufacturing industry.
(Image credit: AdoebStock/wavebreak3)
Ray Kaczmarek joins Nanoscope Therapeutics as the company’s Chief Technology and Manufacturing Officer.
Sulagna Bhattacharya, Co-founder and Chief Executive Officer of Nanoscope spoke to his Kaczmarek’s previous experience in the gene therapy space in the company’s press release.1 She said, "Ray brings a wealth of expertise in building and sustaining gene therapy manufacturing programs. His operational leadership will be crucial to developing the commercial supply of our future therapies as we advance towards potential commercialization."
Nanoscope highlighted the career journey of Kaczmarek and his background of executive leadership and operational expertise in the gene therapy manufacturing industry. Most recently, he served as Chief Executive Officer of Genezen, a contract development and manufacturing organization (CDMO) specializing in viral vector process development, GMP manufacturing, and analytical services. Prior to Genezen, Kaczmarek served as Vice President of GMP Operations at TriLink Biotechnologies, part of Maravai Lifesciences, a CDMO specializing in the synthesis of nucleic acids, GMP capping reagents, plasmids, and oligonucleotides. Kaczmarek also served as Vice President of Manufacturing and Supply Chain Operations at Pacira Biosciences, a leading provider of non-opioid pain management and regenerative health solutions, and, prior to that, he was President of Nitto Avecia, a CDMO specializing in end-to-end solutions for oligonucleotide programs. Mr. Kaczmarek is a graduate of Virginia Tech and a proud veteran of the United States Army.1
Kaczmarek noted his enthusiasm for this new role, saying, "Nanoscope has reached a pivotal juncture in its mission to bring transformative gene therapy products to market. I am excited to contribute my expertise to Nanoscope's programs, and I look forward to leading the build-out of commercial product manufacturing to ensure Nanoscope is ready to bring these much-needed treatments to patients."1
Nanoscope Therapeutics is currently developing gene therapies for retinal degenerative diseases, including retinitis pigmentosa and Stargardt disease.
